Elmiron Lawsuit Update October 2026: 1,989 Cases Filed, 186 Remain — Settlement Status & Who Can Still File
As of October 2026, the Elmiron multidistrict litigation has shrunk from a peak of 1,989 filed cases to just 186 still pending in the U.S. District Court for the District of New Jersey, signaling that years of confidential settlements are winding the case down. If you took Elmiron (pentosan polysulfate sodium) for bladder pain and later developed vision problems, filing may still be possible — but state deadlines are tightening as the litigation nears its end.
Key facts
- 1,989 lawsuits have been filed in the Elmiron MDL since its creation; only 186 remained pending as of October 2026.
- The cases are centralized as MDL No. 2973 in the District of New Jersey before Judge Brian R. Martinotti.
- Janssen, Elmiron's maker, updated the drug's label in June 2020 to warn of "changes in the retina of the eye (pigmentary maculopathy)."
- Settlements have been resolving cases confidentially since 2023; no public amounts and no jury verdicts have been announced.
- The MDL began with just 42 cases when the Judicial Panel on Multidistrict Litigation centralized them on December 15, 2020.
What Elmiron Is — and the Injury at the Heart of the Claims
Elmiron (the brand name for pentosan polysulfate sodium, or PPS) is a prescription medication taken for interstitial cystitis — a chronic condition causing bladder pain and discomfort. Pigmentary maculopathy is a distinctive eye disorder involving damage to the retinal pigment beneath the retina, and it can progress to permanent vision loss. Plaintiffs allege long-term Elmiron use caused exactly this injury, and that Janssen failed to warn patients and doctors for years after the first studies connecting the drug to the eye condition appeared in 2018. Because interstitial cystitis disproportionately affects women, the overwhelming majority of plaintiffs are women.
For broader context on how drug-injury claims are evaluated, see our overview of Elmiron lawyer guidance.
October 2026: The Docket Is Nearly Empty
The headline of this update is the trajectory: 1,989 filed, 186 left. That steep decline from the ~1,900-case peak is the clearest public signal that resolution activity has been heavy. In August 2026, the Judicial Panel on Multidistrict Litigation still listed MDL No. 2973 among its active dockets, and the New Jersey court continues managing what remains.
How the Litigation Got Here
Studies tying Elmiron to an unusual pattern of pigmentary maculopathy surfaced in 2018, and patients began filing lawsuits soon after. In June 2020, the FDA advised Janssen to add a retinal-damage warning — a change plaintiffs' attorneys cite as evidence the company knew or should have known. On December 15, 2020, the JPML created MDL No. 2973, consolidating 42 federal cases before Judge Martinotti. The docket then exploded: 1,041 cases by June 2022, 1,926 by October 2022. The first bellwether trial — a test case chosen to gauge how juries respond, here the case of Louisiana patient Maria Windham — was slated for early 2023. It never happened: the parties withdrew motions in April 2023, widely read as a sign that settlement negotiations had taken over, and the bellwether program was postponed.
Where Settlements Stand — and What Happens Next
Janssen has been resolving Elmiron cases through individual and group settlements since 2023, all confidential. No global settlement has been publicly announced and no jury has rendered a verdict. The shrinking docket suggests the manufacturer is actively clearing the inventory, with remaining cases likely involving more complex claims or plaintiffs seeking higher compensation. In August 2023 the court approved the Elmiron Fee Fund and Expense Fund — qualified settlement funds for disbursing common-benefit money — further evidence that settlement machinery was being built. Compensation varies widely by case, and most settlements are confidential; be skeptical of any website promising a specific dollar outcome. With bellwether trials indefinitely postponed, the most likely path is continued confidential resolution through 2027 rather than headline verdicts.
Who May Still Qualify for a Claim
You may qualify if you: (1) took Elmiron or generic pentosan polysulfate sodium for interstitial cystitis or bladder pain, (2) were later diagnosed with pigmentary maculopathy, retinal damage, or unexplained vision loss, and (3) have pharmacy and medical records documenting both the Elmiron use and the eye condition. Many patients were initially misdiagnosed with age-related macular degeneration before the Elmiron connection was understood — a misdiagnosis history does not disqualify you. Vision-related drug injuries follow similar evidentiary patterns; our guide to Ozempic vision-loss claims explains how lawyers document medication-to-eye-injury cases.
Deadlines: Why the Discovery Rule Matters Here
Statutes of limitations for product-liability claims are typically two to four years — but under the discovery rule, the clock generally starts when you knew or should have known the drug caused your injury, not when you first noticed vision trouble. Because the Elmiron–maculopathy link only became widely known after 2018 and the label warning arrived in 2020, plaintiffs diagnosed years ago may still have live claims in some states. A consultation costs nothing and preserves nothing by waiting. This litigation sits alongside related consumer-injury cases — for example, the EzriCare eye drops litigation — so firms are well practiced at handling these records.
If you took Elmiron and have unexplained vision problems, the practical step is simple: get a retinal exam, gather your pharmacy records, and speak with a mass-tort attorney promptly. For more on drug-safety litigation, follow our Problem Solved channel on YouTube.
Who Benefits From This — and Who Does Not
Who benefits most from this guide:
Patients who took Elmiron or generic pentosan polysulfate sodium for interstitial cystitis or bladder pain and were later diagnosed with pigmentary maculopathy, retinal damage, or unexplained vision loss. How: the qualifying pattern is pharmacy records documenting the Elmiron use plus medical records documenting the eye condition.
Patients who were first misdiagnosed with age-related macular degeneration. How: a misdiagnosis history does not disqualify you, because many patients were misdiagnosed before the Elmiron connection was understood.
Patients who only recently connected their vision problems to the drug. How: under the discovery rule the clock generally starts when you knew or should have known the drug caused your injury, not when you first noticed vision trouble, so plaintiffs diagnosed years ago may still have live claims in some states.
Who does not benefit:
Anyone expecting a public settlement amount to be announced. How: all settlements to date have been confidential, no global settlement figure has been made public, and no jury has rendered a verdict, even as the docket fell from 1,989 filed cases to 186 pending.
Anyone without both Elmiron use and an eye diagnosis in the records. How: these claims need the drug, the injury, and records connecting them, and a consultation costs nothing to evaluate whether that connection exists.
Anyone who keeps waiting while the litigation winds down. How: statutes of limitations for product-liability claims are typically two to four years, and state deadlines are tightening as the litigation nears its end, so an evaluation sooner is safer than later.
A related eye-injury litigation with its own individual-filing path is covered in our guide to the EzriCare eye drops cases, where no settlement has been announced either.
FAQ
Can I still file an Elmiron lawsuit in 2026?
Potentially, yes. Lawyers are still evaluating Elmiron claims, and the discovery rule may extend deadlines for patients who only recently connected their vision problems to the drug. But statutes of limitations vary by state, so an evaluation sooner is safer than later.
What eye injuries qualify for an Elmiron claim?
Pigmentary or retinal maculopathy is the signature injury, but claims have also involved macular degeneration, retinal pigmentary changes, and unexplained vision loss diagnosed after long-term Elmiron use.
Has there been an Elmiron settlement amount announced?
No. All settlements to date have been confidential, and no global settlement figure has been made public. The steady drop from 1,989 filed cases to 186 pending strongly suggests substantial confidential resolution, but the amounts are not disclosed.
How much does it cost to hire an Elmiron lawyer?
Most mass-tort firms handle Elmiron cases on a contingency basis, meaning no upfront legal fees — the firm is paid a percentage of any recovery. There is no out-of-pocket cost to have your case evaluated.
Who benefits most from an Elmiron claim evaluation?
Patients who took Elmiron for interstitial cystitis and were later diagnosed with pigmentary maculopathy, retinal damage, or unexplained vision loss benefit most, especially when pharmacy records document the drug use and medical records document the eye condition, including patients first misdiagnosed with age-related macular degeneration.
How do I start an Elmiron claim?
Get a retinal exam, gather your pharmacy records and the medical records for the eye condition, and speak with a mass-tort attorney promptly, since statutes of limitations vary by state and the discovery rule may extend deadlines only for patients who recently connected their vision problems to the drug. Most firms evaluate these cases on contingency, with no upfront legal fees.
Disclaimer: This article is general information about a pending litigation and is not legal advice. Consult a qualified attorney about your specific situation.